Forget ephedrine – ever heard of dextropropoxyphene?

‘Shahabuddin allowed company to import 5,000kg of another controlled substance’.


Arif Rana June 22, 2012
Forget ephedrine – ever heard of dextropropoxyphene?

ISLAMABAD:


Already faced with the ephedrine case, another controlled substance-related scandal is shaping up against Makhdoom Shahabuddin.


Records from the devolved federal health ministry indicate that Shahabuddin, during his tenure as health minister, also allowed Danas Pharmaceutical to import 5,000kg of dextropropoxyphene, a controlled substance used in the manufacture of the medical drug darvon, from India in 2010, reliable sources told The Express Tribune.

Danas Pharmaceutical is also one of the two pharmaceutical companies alleged to have benefitted from the ephedrine scandal.

According to the devolved health ministry’s record, Imran Gilani, a partner of Danas Pharmaceutical Islamabad with ties to the Pakistan Peoples Party (PPP), submitted a written request to Shahabuddin in 2010, seeking a no objection certificate (NOC) for the import of 5,000kg of dextropropoxyphene from India. Shahabuddin is said to have accepted Gilani’s request forthwith; in his capacity as a health minister, he is alleged to have directed then director general Health Asad Hafeez to issue the NOC in clear violation of the 1976 Drug Act.

According to the Drug Act, dextropropoxyphene’s one time quota cannot exceed 500kg since, like ephedrine, chances of its misuse are high.

Danas Pharmaceutical, in its request, maintained the 5,000kg dextropropoxyphene quota was intended for flood victims. Industry experts, however, say this was just an excuse to obtain permission for the import of the controlled substance which could later be used to manufacture addictive pills.

In early 2011, the health secretary, on Shahabuddin’s direction, reinstated the ban on dextropropoxyphene import.

The ban orders, however, contained special instructions for Danas Pharmaceutical to dispose the 5,000kg quota it had imported. On receipt of the ban orders, Imran Gilani sought permission on behalf of the company to use the quota. A formal request was then submitted to the health secretary, who subsequently constituted a committee to look into the issue and suggest appropriate measures. Despite numerous meetings with a team from Danas Pharmaceutical, however, the committee could not reach a final decision.


Published in The Express Tribune, June 22nd, 2012.

COMMENTS (24)

how to choice cheap Cheap Gucci Handbags | 12 years ago | Reply My wife and i have been now thrilled that Edward managed to do his studies through the ideas he obtained out of the blog. It is now and again perplexing to just always be making a gift of instructions some other people have been making money from. Therefore we do understand we now have the writer to be grateful to for this. The most important illustrations you have made, the easy website menu, the friendships you will give support to create - it is everything amazing, and it is facilitating our son in addition to the family feel that this situation is cool, which is certainly rather serious. Thank you for all the pieces!
K Niaz | 12 years ago | Reply

Dextropropoxyphene has been withdrawn from markets in EU and the USA since 2007 for the very reason for its side effects including high potential of abuse and dependence and did not present any added benefit than the score of opioid painkillers available in the markets.

One wonders why Health Ministry would allow a banned substance to be allowed for import. And what would be the need for a potent pain killer, with such potentials of abuse, for flood victims.

There are reports that in many parts of Pakistan including Southern and Central Punjab where ex heroin users are now injecting all the readily available, cheaper and potent opioid pain killers that are either smuggled or have been produced illicitly as probably the case above.

VIEW MORE COMMENTS
Replying to X

Comments are moderated and generally will be posted if they are on-topic and not abusive.

For more information, please see our Comments FAQ